Latest Data


« Topic Nexavar Approved For Liver Cancer (healthday) | Main | Topic Timely Cancer Diagnosis Linked To Insurance Status (healthday) »

Topic Phase Iii Study Of Bosatria (mepolizumab) Showed Disease Control With Reduced Corticosteroid Use In Hypereosinophilic Syndrome

By admin2 | April 28, 2008

MedicalResults from a Phase III study demonstrate that significantly more patients who received GlaxoSmithKline’s investigational monoclonal antibody, Bosatria® (mepolizumab), for the treatment of hypereosinophilic syndrome (HES), were able to maintain control of their disease with a reduced dose of a corticosteroid, compared to those who received placebo (84% vs. 43%, p
(Link)

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • StumbleUpon
  • Digg
  • del.icio.us
  • Reddit
  • Furl
  • Junipo

Topics: Cancer |

Comments